Johnson & Johnson and partner Sanofi will stop a late-stage trial of an experimental vaccine to prevent infections caused by ...

Johnson & Johnson said on Thursday it will discontinue a late-stage study of an experimental E.coli vaccine it was developing ...

Johnson & Johnson and Sanofi said that while the vaccine showed no safety concerns, it did not meet the necessary ...

The company said it will stop the Phase III trial of ExPEC after interim results found it failed to demonstrate efficacy over ...

An E coli infection linked to the death of a doctor in Princess Margaret Hospital is unlikely to lead to widespread ...

The deceased doctor who was part of a suspected Shiga toxin-producing E coli cluster at a Hong Kong public hospital has been ...

Due to the discontinuation, Sanofi said that it has recorded an impairment charge before tax of $250 million in the Q4 2024 ...

A comprehensive seven-year study across 20 Chinese provinces has revealed a concerning rise in antimicrobial resistance (AMR) ...

Review of data from the trial found that the vaccine was not sufficiently effective at preventing invasive E coli disease ...

The avian specific form of E. coli can lead to an infection called colibacillosis that can cause septicemia, organ failure and death.

Doctor’s age and bacteria’s nature prompt check of possible causes such as chemical exposure, autoimmune issues and radiation ...

The French drugmaker said the vaccine it agreed to develop with Johnson & Johnson a year ago was “not sufficiently effective.